ContraFect (CFRX) Enters Warrant Exercise Transaction for Proceeds of $9.6M

Go back to ContraFect (CFRX) Enters Warrant Exercise Transaction for Proceeds of $9.6M

ContraFect Enters Into a Warrant Exercise Transaction for Proceeds of $9.6 Million

June 27, 2023 8:30 AM UTC

YONKERS, N.Y., June 27, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announces today that it has entered into a warrant exercise agreement with an existing accredited investor to exercise certain outstanding warrants to purchase an aggregate of 7.0 million shares of the company's common... More